Active — Not RecruitingNot Applicable

Biomarkers and Event Patterns of Vascular Disease in Hemodialysis

Austria475 participantsStarted 2022-10-15

Plain-language summary

Parathyroid hormone (PTH) remains the central biomarker to classify CKD-metabolic bone disease (CKD-MBD) in hemodialysis patients. While PTH-values are known to be associated with adverse outcomes, interventional studies have failed to show a benefit of pharmacological modulation of PTH levels on hard clinical outcomes. To address this gap, the investigators explored alternative markers of bone metabolism, vascular calcification and inflammation in association to prospective event patterns.

Who can participate

Age range18 Years – 100 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Stable hemodialysis \> 3 months duration Exclusion Criteria: * Pregnancy * Acute infections or antibiotic treatment (within 4 weeks)

What they're measuring

Mortality

Timeframe: 1, 2 and 3 years

Trial details

NCT IDNCT07170761

SponsorMedical University of Graz

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-12-31

View on ClinicalTrials.gov More Vascular Disease trials